Patents Assigned to MEDIRISTA BIOTECHNOLOGIES AB
  • Oxidized cardiolipin as a pro-inflammatory factor
    Patent number: 10060908
    Abstract: Low levels of antibodies reactive with oxidized Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunization and therapy of these diseases and conditions are provided.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: August 28, 2018
    Assignee: MEDIRISTA BIOTECHNOLOGIES AB
    Inventor: Johan Frostegård
  • Oxidized Cardiolipin as a Novel Pro-Inflammatory Factor
    Publication number: 20140363450
    Abstract: Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 11, 2014
    Applicant: MEDIRISTA BIOTECHNOLOGIES AB
    Inventor: Johan FROSTEGÅRD